Related Experiment Video
Updated: Apr 21, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Atomic connectomics signatures for characterization and differentiation of mild cognitive impairment
1School of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou, China.
Abstract:
In recent years, functional connectomics signatures have been shown to be a very valuable tool in characterizing and differentiating brain disorders from normal controls. However, if the functional connectivity alterations in a brain disease are localized within sub-networks of a connectome, then accurate identification of such disease-specific sub-networks is critical and this capability entails both fine-granularity definition of connectome nodes and effective clustering of connectome nodes into disease-specific and non-disease-specific sub-networks. In this work, we adopted the recently developed DICCCOL (dense individualized and common connectivity-based cortical landmarks) system as a fine-granularity high-resolution connectome construction method to deal with the first issue, and employed an effective variant of non-negative matrix factorization (NMF) method to pinpoint disease-specific sub-networks, which we called atomic connectomics signatures in this work. We have implemented and applied this novel framework to two mild cognitive impairment (MCI) datasets from two different research centers, and our experimental results demonstrated that the derived atomic connectomics signatures can effectively characterize and differentiate MCI patients from their normal controls. In general, our work contributed a novel computational framework for deriving descriptive and distinctive atomic connectomics signatures in brain disorders.
Related Concept Videos
Alzheimer Disease l: Introduction
Dementia l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer Disease ll: Pathophysiology
Dementia
The progression of dementia is generally gradual....

